Australia · Delayed Price · Currency is AUD Echo IQ Earnings Call Transcripts
Fiscal Year 2026
-
Expanded commercial agreements with Mayo Clinic and Mount Sinai position the company for rapid U.S. growth pending FDA clearance. The sales pipeline is robust, with high confidence in regulatory and reimbursement progress, and significant revenue ramp expected in the second half of the year.
Fiscal Year 2025
-
AI-powered echocardiogram diagnostics are driving rapid commercialization, with FDA clearance for aortic stenosis achieved and heart failure submission underway. Major hospital integrations, a robust product pipeline, and a SaaS model set the stage for significant revenue growth and a potential U.S. IPO in 2026.
-
A novel AI platform enables real-time, highly accurate diagnosis of heart disease from echocardiogram data, with FDA-cleared aortic stenosis detection and a heart failure solution nearing submission. Integration with major hospitals and strong clinical validation support rapid U.S. expansion and revenue growth in 2026.
-
EchoSolve HF achieved 99.5% sensitivity and 91% specificity in a major Mayo Clinic validation, supporting imminent FDA submission and large-scale US commercialization. The platform targets significant unmet needs in heart failure and aortic stenosis, with a robust pipeline and global expansion plans.